Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

Summary Background Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in
multiple B-cell malignancies, but patients discontinue these agents due to resistance and …

Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia
(CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The …

Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an
aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics …

Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–
modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who …

Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …

Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …

Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia
showed that its side effects differ from those of traditional chemotherapy. Reasons for …

Background Deletion of chromosome 17p (del [17p]) in patients with chronic lymphocytic
leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy …